Arcus Biosciences Inc

20 de ago. de 2026, 19:36 UTC

Arcus Biosciences shares are lower, reflecting a broader decline in the biotechnology sector amid first-quarter results indicating a notable drop in price.

19 de ago. de 2026, 19:46 UTC

Arcus Biosciences Inc is trading higher, supported by a positive trend in the biotechnology sector. The stock remains above its 20-day moving average.

18 de ago. de 2026, 20:06 UTC

Arcus Biosciences Inc. shares are trading roughly flat amid no specific news. The stock remains above its 20-day moving average.

17 de ago. de 2026, 19:16 UTC

Arcus Biosciences Inc is rising as biotechnology sector momentum continues. The company reported second-quarter revenue of $41 million and a net loss of $91 million.

14 de ago. de 2026, 19:46 UTC

Arcus Biosciences Inc is higher today, continuing a positive trend since Thursday's close. The stock remains above its 20-day moving average.

11 de ago. de 2026, 19:56 UTC

HC Wainwright raised Arcus Biosciences' Q3 2026 EPS estimate to -$1.00 and maintained a "Buy" rating with a price target of $45.00.

10 de ago. de 2026, 21:02 UTC

Arcus Biosciences Inc shares are higher in after-market trading, continuing a strong upward trend since Monday's close, well above the 20-day moving average.

7 de ago. de 2026, 19:36 UTC

Arcus Biosciences Inc. shares are higher today, trading within a typical range amid investor uncertainty over future monetary policy following a weak jobs report.

6 de ago. de 2026, 20:03 UTC

Arcus Biosciences shares are higher as Wells Fargo raises its price target to $23.00 and Wedbush increases its target to $43. Trading volume is notably high.

5 de ago. de 2026, 20:21 UTC

Arcus Biosciences reported a net loss of $91 million but exceeded revenue expectations with $41 million. Shares are higher in after-market trading.

4 de ago. de 2026, 21:02 UTC

Arcus Biosciences Inc shares are higher in after-market trading, reflecting positive market sentiment amid easing inflation concerns from U.S.-Iran negotiations.

3 de ago. de 2026, 19:36 UTC

Arcus Biosciences shares are lower today, reflecting broader market dynamics and geopolitical developments impacting investor sentiment. Earlier, shares peaked before declining.

31 de jul. de 2026, 23:16 UTC

Arcus Biosciences Inc. shares are lower in after-market hours, continuing a trend of declining prices and remaining below the 20-day moving average.

30 de jul. de 2026, 18:03 UTC

Arcus Biosciences Inc gains today, supported by a broader market uptick despite geopolitical tensions and inflation concerns. Shares pulled back from earlier session highs.

29 de jul. de 2026, 19:56 UTC

Arcus Biosciences shares are lower amid broader market pressures from steady interest rates and rising crude oil prices, marking five consecutive sessions of decline.

28 de jul. de 2026, 20:06 UTC

Arcus Biosciences Inc shares are lower today, reflecting broader market trends and declines in Asian markets, including significant losses in the Nikkei 225 Index.

27 de jul. de 2026, 21:01 UTC

Arcus Biosciences Inc shares declined in after-market hours, continuing a downward trend over the last four sessions. No specific news was identified to explain the move.

24 de jul. de 2026, 19:06 UTC

Arcus Biosciences has signed a clinical supply agreement with AVEO to evaluate casdatifan with tivozanib. Shares are trading lower, reflecting unusual weakness.

22 de jul. de 2026, 20:13 UTC

Arcus Biosciences shares are higher in after-market hours. Broader market volatility is influenced by rising crude oil prices and geopolitical tensions.

21 de jul. de 2026, 19:36 UTC

Arcus Biosciences shares are higher today, supported by overall market strength and positive sentiment in the biotechnology sector. The stock has advanced notably since Monday.

20 de jul. de 2026, 18:06 UTC

H.C. Wainwright raised Arcus Biosciences' price target to $45 from $32, maintaining a Buy rating. Shares are higher today following the analyst's upgrade.